Can NewLink Genetics Win the Zika Vaccine Race?
Does NewLink's success with Ebola suggest it can do the same with Zika?
3 Things to Look for in Regeneron Pharmaceuticals Inc.'s Earnings
From Eylea sales to the late-stage pipeline, here are the three areas this Fool will be watching in Regeneron's fourth-quarter report.
Novo Nordisk A/S Taps the Growth Brakes
The diabetes specialist expects to see slowing operating growth, but it has a good reason.
Is Inovio Pharmaceuticals' Zika Surge Premature?
The biotech's stock has heated up recently with fears about the Zika virus. Too much too fast?